S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NASDAQ:CMMB

Chemomab Therapeutics (CMMB) Stock Forecast, Price & News

$1.70
-0.03 (-1.73%)
(As of 06/5/2023 ET)
Compare
Today's Range
$1.63
$1.76
50-Day Range
$1.42
$1.84
52-Week Range
$1.38
$5.35
Volume
17,892 shs
Average Volume
524,875 shs
Market Capitalization
$18.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Chemomab Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
311.8% Upside
$7.00 Price Target
Short Interest
Healthy
4.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Chemomab Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.70) to ($1.20) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

766th out of 985 stocks

Pharmaceutical Preparations Industry

381st out of 483 stocks


CMMB stock logo

About Chemomab Therapeutics (NASDAQ:CMMB) Stock

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Receive CMMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CMMB Stock News Headlines

Biden's latest bailout--terrible for America?
And a consultant for the Dept. of Defense (Joel Litman) says this is all leading to an event in the next 20 months that could help some get vastly wealthier… but also make it harder than ever to hang onto any money you make.This might be the most important development affecting you and your money over the next few years—
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Chemomab Therapeutics (NASDAQ:CMMB) PT Lowered to $7.00
Chemomab Therapeutics (CMMB) Set to Announce Earnings on Friday
See More Headlines

CMMB Price History

CMMB Company Calendar

Last Earnings
3/20/2023
Today
6/06/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CMMB
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+311.8%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-27,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.11 per share

Miscellaneous

Free Float
9,734,000
Market Cap
$18.79 million
Optionable
Not Optionable
Beta
0.35

Key Executives

  • Dr. Dale R. Pfost Ph.D. (Age 65)
    Chairman & CEO
    Comp: $192k
  • Dr. Adi Mor George Ph.D. (Age 40)
    Co-Founder, Chief Scientific Officer & Exec. Director
    Comp: $480k
  • Mr. Donald R. Marvin MBA (Age 69)
    CFO, Exec. VP & COO
    Comp: $94k
  • Barbara Lindheim
    Consulting VP of Investor & PR, Strategic Communications
  • Mr. Mitchell Lawrence Jones M.D.
    Ph.D., VP of Corp. Devel. & Strategy
  • Dr. Matthew Frankel M.B.A.
    M.D., Chief Medical Officer & VP of Drug Devel.













CMMB Stock - Frequently Asked Questions

What is Chemomab Therapeutics' stock price forecast for 2023?

0 analysts have issued 12 month price objectives for Chemomab Therapeutics' stock. Their CMMB share price forecasts range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next year. This suggests a possible upside of 311.8% from the stock's current price.
View analysts price targets for CMMB
or view top-rated stocks among Wall Street analysts.

How have CMMB shares performed in 2023?

Chemomab Therapeutics' stock was trading at $3.20 at the beginning of 2023. Since then, CMMB shares have decreased by 46.9% and is now trading at $1.70.
View the best growth stocks for 2023 here
.

Are investors shorting Chemomab Therapeutics?

Chemomab Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 422,900 shares, a decrease of 7.3% from the April 30th total of 456,300 shares. Based on an average trading volume of 74,000 shares, the days-to-cover ratio is presently 5.7 days. Currently, 4.8% of the shares of the stock are sold short.
View Chemomab Therapeutics' Short Interest
.

When is Chemomab Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our CMMB earnings forecast
.

How were Chemomab Therapeutics' earnings last quarter?

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) released its quarterly earnings data on Monday, March, 20th. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.80) by $0.08.

What is Chemomab Therapeutics' stock symbol?

Chemomab Therapeutics trades on the NASDAQ under the ticker symbol "CMMB."

Who are Chemomab Therapeutics' major shareholders?

Chemomab Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Two Sigma Investments LP (0.27%) and Boothbay Fund Management LLC (0.24%). Insiders that own company stock include Dale R Pfost, Donald Marvin, George Adi Mor, Israel Gp Ltd Orbimed, Joel Michael Maryles and Neil Harris Cohen.
View institutional ownership trends
.

How do I buy shares of Chemomab Therapeutics?

Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chemomab Therapeutics' stock price today?

One share of CMMB stock can currently be purchased for approximately $1.70.

How much money does Chemomab Therapeutics make?

Chemomab Therapeutics (NASDAQ:CMMB) has a market capitalization of $18.79 million. The company earns $-27,650,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis.

How can I contact Chemomab Therapeutics?

Chemomab Therapeutics' mailing address is KIRYAT ATIDIM BUILDING 7, TEL AVIV L3, 6158002. The official website for the company is www.chemomab.com. The company can be reached via phone at 972-77-331-0156 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:CMMB) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -